Patent details

LUC00334 Product Name: elvitégravir et ténofovir alafénamide

Basic Information

Publication number:
LUC00334
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP171866742
Legal Status:
Active
Application number:
LUC00334
First applicant's nationality:
Procedural language:
French

Paediatric Extension

SPC Extension Filing Date:
18/03/2024
SPC Extension Agent Name:
OFFICE FREYLINGER S.A.
SPC Extension Status:
Granted
SPC Extension Grant Date:
04/08/2025
SPC Extension Rejection Date:

Marketing Authorization

Marketing Authorization Number:
EU/1/15/1061
Marketing Authorization Type:
Marketing Authorization Date:
23/11/2015
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
14/03/2024
First Marketing Authorization date:
23/11/2015
Grant date:
01/07/2024
Activation date:
19/05/2025
Publication date:
15/03/2024
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
19/05/2030
SPC Extension Expiration:
19/11/2030
Rejection date:
Withdrawal date:

Owner

From:
14/03/2024
 
 

Name:
Japan Tobacco Inc.
Address:
1-1, Toranomon 4-chome Minato-ku, Tokyo 105-6927, Japan (JP)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
14/03/2024
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC2
Bulletin edition number:
2024/10
Publication date:
06/08/2024
Description:
Section D : Granted supplementary protection certificates – I2 publication

2

Bulletin Heading:
SPC1
Bulletin edition number:
2024/05
Publication date:
03/04/2024
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

3

Bulletin Heading:
SPCX1
Bulletin edition number:
2024/05
Publication date:
03/04/2024
Description:
Section G : Applications for extensions for pediatric use – I1E publication

4

Bulletin Heading:
SPC3
Bulletin edition number:
2025/07
Publication date:
04/06/2025
Description:
Section E : Supplementary Protection certificates entered into force – IA publication

Annual Fees

Annual Fee Due Date:
01/06/2026
Annual Fee Number:
22
Annual Fee Amount:
420 Euro
Expected Payer:
Last Annual Fee Payment Date:
16/05/2025
Last Annual Fee Paid Number:
21
Last Annual Fee Paid Amount:
410 Euro
Payer:
CPA GLOBAL THE IP PLATFORM
Filing date Document type Number of pages
15/03/2024 Publication 1
01/07/2024 Publication 1
01/07/2024 Certificate 1
08/07/2024 Outgoing Correspondence 1
14/03/2024 MA publication 11
14/03/2024 Application Form 3
14/03/2024 Marketing authorization 3
14/03/2024 Summary of the product caracteristics 49
15/03/2024 Outgoing Correspondence 1
18/03/2024 Outgoing Correspondence 1
18/03/2024 Application Form 3
18/03/2024 Marketing authorization 3
18/03/2024 Summary of the product caracteristics 62
18/03/2024 Paediatric investigation plan 1
04/08/2025 Outgoing Correspondence 1
18/03/2024 Publication 1
18/03/2024 FNET_DC_FRONTPAGE 1
07/08/2025 Certificate 1
07/08/2025 Publication 1